drugset
drugset / Trial / NCT00724100

A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors

NCT00724100 ↗

Phase 1 Terminated 46 enrolled Albany Molecular Research, Inc. Westat · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose of ALB 109564(a), a novel tubulin inhibitor, and to assess safety, pharmacokinetics, and anti-tumor activity in subjects with advanced solid tumors.

Timeline

Start
2008-09
Primary completion
2010-12
Completion
2010-12

Outcome

Outcome not reported

Stopped: “Sponsor's decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject ALB 109564(a) Unknown 1.2 mg/m2 Intravenous

Indications

cancer